- E-mailastrid.borretzen@uib.no
- Visitor AddressHaukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst5009 Bergen
- Postal AddressPostboks 78045020 Bergen
Academic article
- (2023). Microvascular proliferation is associated with high tumour blood flow by mpMRI and disease progression in primary prostate cancer. Scientific Reports.
- (2023). A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer. Cancer Immunology and Immunotherapy.
- (2022). PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progression. Nature Communications. 1-19.
- (2021). The epithelial–mesenchymal transition regulators Twist, Slug, and Snail are associated with aggressive tumour features and poor outcome in prostate cancer patients. The journal of pathology. Clinical research. 253-270.
- (2019). FOXC2 expression and epithelial–mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer. The journal of pathology. Clinical research. 272-286.
Academic lecture
- (2023). Survival and biomarkers in a prospective non-randomized phase I trial of dendritic cell-based cryoimmunotherapy combined with checkpoint inhibitors in metastatic castration-resistant prostate cancer (mCRPC) .
Short communication
- (2023). A prospective non-randomized phase I trial of dendritic cell–based cryoimmunotherapy combined with checkpoint inhibitors in mCRPC. Journal of Clinical Oncology.
Abstract
- (2013). Does GEWF solution improve lymph node harvest in colorectal cancer specimens with and without neoadjuvant therapy? Virchows Archiv. 210-211.
Poster
- (2023). Survival and biomarkers in a prospective non-randomized phase I trial of dendritic cell-based cryoimmunotherapy combined with checkpoint inhibitors in metastatic castration-resistant prostate cancer (mCRPC).
More information in national current research information system (CRIStin)